New research shows that young breast cancer patients with high-risk genes may be able to prevent their cancer from returning ...
Medpage Today on MSN2d
Risk-Reducing Surgery May Benefit BRCA Carriers With Early-Onset Breast CancerCarriers of germline BRCA mutations diagnosed with breast cancer by age 40 who underwent risk-reducing surgeries had lower ...
The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...
Several biomarkers may predict improved treatment responses and outcomes in patients with triple-negative breast cancer.
AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...
Merck hasn’t had much luck pairing cancer superstar Keytruda with PARP inhibitor Lynparza. | Merck hasn’t had much luck ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback